Clinical evaluation of patients with psychiatric disorders is mainly dependent on patients' reports and clinicians' observations. In order to develop objective and quantifiable measures of psychopathology, molecular imaging techniques will be used in patients receiving clozapine.
Age
19–45
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Overtly healthy males as determined by medical history and physical examination
Age from 19 to 45 years
Weight ≥ 45 kg and within ± 20% of IBW
Clinical laboratory test results within normal reference range for the National Cancer Center, Hospital or results with minor deviations which are judged to be not clinically significant by the investigator
Normal blood pressure and heart rate (supine and standing) as determined by the investigator
Are reliable and willing to make themselves available for the duration of the study, and who will abide by the study restrictions
Have given written informed consent
You may not be if
Evidence of significant active hematologic disease
History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, neurological disorders capable of altering the absorption, metabolism or elimination of drugs, or of constituting a risk factor when taking the study medication
An episode of febrile disease or infectious disease within the past 2 weeks
Evidence of significant active neuropsychiatric disease
Regular use of drugs or abuse
History of drug hypersensitivity or clinically significant allergic reactions of any origin
Participation in a study involving administration of an investigational compound within the past 30 days
